<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679029</url>
  </required_header>
  <id_info>
    <org_study_id>412-07</org_study_id>
    <secondary_id>NCI-2009-01693</secondary_id>
    <secondary_id>P30CA036727</secondary_id>
    <nct_id>NCT00679029</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer</brief_title>
  <official_title>Adjuvant Doxorubicin, Cyclophosphamide Followed by Avastin Given With Paclitaxel and Gemcitabine for Stage II and III Breast Cancer That Does Not Over-express HER-2/Neu</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide,
      paclitaxel, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,
      such as bevacizumab, can block tumor growth in different ways. Some block the ability of
      tumor cells to grow and spread. Others find tumor cells and help kill them or carry
      tumor-killing substances to them. Bevacizumab may also stop the growth of breast cancer by
      blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab
      after surgery may kill any tumor cells that remain after surgery.

      PURPOSE: This phase II trial is studying the side effects and how well giving combination
      chemotherapy together with bevacizumab works in treating women with HER2/neu-negative stage
      II or stage III breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the feasibility of administering two sequential chemotherapy doublets with
      Avastin in the adjuvant setting.

      II. To assess the safety of Avastin in the adjuvant setting particularly regarding cardiac
      function, wound healing and toxicity of radiation.

      SECONDARY OBJECTIVES:

      I. To determine the effect of Avastin on immunity, especially VEGF-A upregulation of MDSC and
      suppression of T-Cells.

      II. To determine the effect of therapy on numbers of myeloid derived suppressor cells and
      compare the humoral and cellular response to p53 in breast cancer patients treated with the
      same chemotherapy.

      III. Patients will be followed for freedom from tumor progression and survival.

      OUTLINE:

      COURSES 1-4: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1
      and pegfilgrastim subcutaneously (SC) on day 1. Treatment repeats every 2 weeks for 4 courses
      in the absence of unacceptable toxicity or disease progression.

      COURSES 5-7: Patients receive paclitaxel IV and gemcitabine hydrochloride IV on day 1 and
      pegfilgrastim SC on day 1. Patients also receive bevacizumab IV on day 1 in courses 5-7.
      Treatment repeats every 2 weeks for 4 courses in the absence of unacceptable toxicity or
      disease progression.

      COURSES 8-16: Patients receive bevacizumab IV alone on day 1. Treatment repeats every 3 weeks
      for 8 courses in the absence of unacceptable toxicity or disease progression.

      After course 8, patients may undergo radiotherapy and hormone therapy, if clinically
      indicated.

      After completion of study treatment, patients are followed every 3 months for 2 years and
      then every 6 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    drug toxicity
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Study Drug-associated Adverse Events Leading to Dose Holds or Reductions</measure>
    <time_frame>through study completion, an average of 10 months</time_frame>
    <description>This outcome is to measure the feasibility of the of administering two sequential chemotherapy doublets with Avastin in the adjuvant setting in women with stage II and III breast cancer that does not over-express HER 2/neu</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Count of Participants With Related SAEs by NCI Common Toxicity Criteria v3.0</measure>
    <time_frame>through study completion, an average of 10 months</time_frame>
    <description>Assess the safety of Avastin in the adjuvant setting particularly regarding cardiac function, wound healing and toxicity of radiation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free Survival as Assessed by the Kaplan and Meier Method</measure>
    <time_frame>From the date of first treatment to the date of disease progression/recurrence, second cancer, or death, whichever came first, assessed up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival as Assessed by the Kaplan and Meier Method</measure>
    <time_frame>From the date of first treatment to the date of death, assessed up to 100 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HER2-negative Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy with Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.
TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.
Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemotherapy with Bevacizumab</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemotherapy with Bevacizumab</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemotherapy with Bevacizumab</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemotherapy with Bevacizumab</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemotherapy with Bevacizumab</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Chemotherapy with Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Chemotherapy with Bevacizumab</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>GCSF-SD01</other_name>
    <other_name>Neulasta</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of invasive breast cancer: By pathologic evaluation, primary
             tumor must be T1-4N1-3M0 or T3-4N 0M0 that is ER/PR positive or negative and HER-2/neu
             negative (1+) immunocytochemistry or not amplified by FISH

          -  OR By pathologic evaluation, primary tumor must be T2N0 that is ER, PR and HER-2neu
             negative

          -  Women of reproductive potential must be non-pregnant and non-nursing and must agree to
             employ an effective barrier method of birth control throughout the study and for up to
             6 months following treatment

          -  Women of child-bearing potential, must have a negative pregnancy test within 7 days of
             initiating study (no childbearing potential is defined as age 55 years or older and no
             menses for two years or any age with surgical removal of the uterus and/or both
             ovaries)

          -  ECOG performance status of 0 or 1

          -  Definitive surgery, lumpectomy and axillary sampling or modified radical mastectomy

          -  Three weeks since last surgery other than port or right atrial catheter placement

          -  No significant cardiac disease and a normal left ventricular ejection fraction

          -  No significant open wounds, uncontrolled hypertension, history of venous or arterial
             clotting

          -  Adequate laboratory parameters within 30 days prior to enrollment defined as:

          -  Absolute neutrophil count greater than or equal to 1,500/mcl

          -  Platelet count equal to or greater than 150,000/mcl

          -  Hemoglobin &gt;11gm/dl

          -  Alkaline phosphatase equal or less than 1.5 times the ULN

          -  Total bilirubin equal to or less than 1.5 times the ULN

          -  AST and ALT no greater than 1.5 times the ULN

          -  Creatinine less than 1.5 times the ULN

          -  Urine protein &lt; 2+ on urinalysis, UPC 1.0 or 24 hour urine &lt; 1 g protein

          -  No active serious infections or other condition precluding chemotherapy

          -  Able to give informed consent

          -  Able to return for treatment and follow-up on the specified days

        Exclusion Criteria:

          -  Prior malignancy; except for adequately treated basal cell or squamous cell skin
             cancer or noninvasive carcinomas, or other cancer from which the patient has been
             disease free for 5 years

          -  Prior chemotherapy or radiation therapy

          -  Breast cancer that over expresses Her-2/neu

          -  Stage IV or metastatic breast cancer

          -  Inability to cooperate with treatment protocol

          -  Any comorbidity or condition which, in the opinion of the investigator, may interfere
             with the assessments and procedures of this protocol

          -  Inadequately controlled hypertension (defined as systolic blood pressure &gt; 150 and/or
             diastolic blood pressure &gt; 100 mmHg on antihypertensive medications

          -  Any prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure

          -  History of myocardial infarction or unstable angina within 12 months of study
             enrollment

          -  Any history of stroke or transient ischemic attack at any time

          -  Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

          -  Symptomatic peripheral vascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to study enrollment

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Proteinuria at screening as demonstrated by either urine protein/creatinine (UPC)
             ratio &gt;= 1.0 at screening OR urinalysis for proteinuria &gt;= 2+ (patients discovered to
             have &gt;= 2+ proteinuria on urinalysis at baseline and undergo a 24 hour urine
             collection and demonstrate &gt; 1g of protein in 24 hours are ineligible)

          -  Known hypersensitivity to any component of Avastin or gemcitabine or other required
             drugs in the study

          -  History of venous or arterial thrombosis

          -  Current, ongoing treatment with full-dose warfarin or its equivalent (i.e.,
             unfractionated and/or low molecular weight heparin) for any reason (ASA okay)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Reed</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <results_first_submitted>November 5, 2018</results_first_submitted>
  <results_first_submitted_qc>December 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2018</results_first_posted>
  <last_update_submitted>December 10, 2018</last_update_submitted>
  <last_update_submitted_qc>December 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Elizabeth Reed, MD</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy With Bevacizumab</title>
          <description>AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.
TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.
Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7.
N=Growth factor pegfilgastrim 6 mg will be administered subcutaneously on day 1 after AC and TG treatment every 2 weeks for 8 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.
TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.
Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7.
N=Growth factor pegfilgastrim 6 mg will be administered subcutaneously on day 1 after AC and TG treatment every 2 weeks for 8 cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&gt;=19 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, Not Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Study Drug-associated Adverse Events Leading to Dose Holds or Reductions</title>
        <description>This outcome is to measure the feasibility of the of administering two sequential chemotherapy doublets with Avastin in the adjuvant setting in women with stage II and III breast cancer that does not over-express HER 2/neu</description>
        <time_frame>through study completion, an average of 10 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.
TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.
Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7.
N=Growth factor pegfilgastrim 6 mg will be administered subcutaneously on day 1 after AC and TG treatment every 2 weeks for 8 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Study Drug-associated Adverse Events Leading to Dose Holds or Reductions</title>
          <description>This outcome is to measure the feasibility of the of administering two sequential chemotherapy doublets with Avastin in the adjuvant setting in women with stage II and III breast cancer that does not over-express HER 2/neu</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="4.33" upper_limit="48.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Count of Participants With Related SAEs by NCI Common Toxicity Criteria v3.0</title>
        <description>Assess the safety of Avastin in the adjuvant setting particularly regarding cardiac function, wound healing and toxicity of radiation.</description>
        <time_frame>through study completion, an average of 10 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.
TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.
Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7.
N=Growth factor pegfilgastrim 6 mg will be administered subcutaneously on day 1 after AC and TG treatment every 2 weeks for 8 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Related SAEs by NCI Common Toxicity Criteria v3.0</title>
          <description>Assess the safety of Avastin in the adjuvant setting particularly regarding cardiac function, wound healing and toxicity of radiation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival as Assessed by the Kaplan and Meier Method</title>
        <time_frame>From the date of first treatment to the date of disease progression/recurrence, second cancer, or death, whichever came first, assessed up to 5 years</time_frame>
        <population>report below of estimated disease free survival at 5 years</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.
TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.
Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7.
N=Growth factor pegfilgastrim 6 mg will be administered subcutaneously on day 1 after AC and TG treatment every 2 weeks for 8 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival as Assessed by the Kaplan and Meier Method</title>
          <population>report below of estimated disease free survival at 5 years</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="38.2" upper_limit="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival as Assessed by the Kaplan and Meier Method</title>
        <time_frame>From the date of first treatment to the date of death, assessed up to 100 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.
TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.
Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7.
N=Growth factor pegfilgastrim 6 mg will be administered subcutaneously on day 1 after AC and TG treatment every 2 weeks for 8 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival as Assessed by the Kaplan and Meier Method</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" lower_limit="36.7" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during Avastin treatment or during a post-treatment follow-up period. (approximately 30 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.
TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.
Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7.
N=Growth factor pegfilgastrim 6 mg will be administered subcutaneously on day 1 after AC and TG treatment every 2 weeks for 8 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colonic perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other, enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other, Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung Infection</sub_title>
                <description>pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decrease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other, cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other, alveolar hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>dermatitis radiation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>hypoalbuminia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other - cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other - respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Elizabeth Reed, Professor of Internal Medicine - Oncology/Hematology</name_or_title>
      <organization>University of Nebraska</organization>
      <phone>402-559-5388</phone>
      <email>ereed@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

